Search
Search
Damon Dierker, OD, FAAO
Show Description +
In this video, Damon Dierker, OD, FAAO, recalls the DEWS II definition of dry eye disease and the vicious cycle of tear-film instability, hyperosmolarity, and ocular inflammation. He describes his patients’ reaction to a nasal spray to treat dry eye. As a Tyrvaya user himself, Dr. Dierker discusses his experience with Tyrvaya-partnered PhilRx pharmacy service.
Posted: 1/06/2023
Damon Dierker, OD, FAAO
In this video, Damon Dierker, OD, FAAO, recalls the DEWS II definition of dry eye disease and the vicious cycle of tear-film instability, hyperosmolarity, and ocular inflammation. He describes his patients’ reaction to a nasal spray to treat dry eye. As a Tyrvaya user himself, Dr. Dierker discusses his experience with Tyrvaya-partnered PhilRx pharmacy service.
Posted: 1/06/2023
The most common adverse reaction reported in 82% of patients was sneezing. Events that were reported in 5-16% of patients were cough, throat irritation, and instillation-site (nose) irritation.
Tyrvaya® (varenicline solution) nasal spray is indicated for the treatment of the signs and symptoms of dry eye disease.
Please click here for full Prescribing Information.
Intended for US healthcare professionals.
© 2022 Oyster Point Pharma, Inc. Oyster Point®, Tyrvaya®, and the Tyrvaya logo are trademarks of Oyster Point Pharma, Inc. in the United States and certain jurisdictions. All rights reserved. All other trademarks are the rights of their respective owners.
About Oyster Point Pharma, Inc.
We are a biopharmaceutical company focused on discovery, development, and commercialization of first-in-class therapies to threat ophthalmic disease. We’re committed to the mission of advancing breakthrough science to deliver therapies that patients and eye care professionals need.
Visit us online: tyrvaya-pro.com
